GlobeNewswire Inc | Jul 12, 2021 08:00AM EDT

July 12, 2021

WILMETTE, Ill., July 12, 2021 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced the appointment of Octvio Costa, MD, as Chief Medical Officer. In this role, Dr. Costa will oversee global clinical development and regulatory affairs, and will provide strategic direction for Monopars pipeline.

Dr. Costa joins Monopar with over 30 years of experience overseeing clinical development, clinical operations, development strategy and global medical affairs. He has extensive Phase 1 through 4 clinical development expertise as well as regulatory experience. Dr. Costas previous roles include positions of increasing responsibility in clinical development at Merck, Celgene, Novartis and most recently as Chief Medical Officer at Rafael Pharmaceuticals. He has played an important role in the development and life-cycle management of significant products, including the blockbuster product REVLIMID (lenalidomide). Dr. Costa earned his Doctor of Medicine from The Medical College of Sorocaba, So Paulo.

We are excited to welcome Octvio, especially as our lead program enters late-stage clinical studies, said Chandler Robinson, MD, Chief Executive Officer of Monopar. Octvios track record of navigating all stages of clinical development will aid Monopar in executing our growing clinical development pipeline.

I am thrilled to be joining this accomplished management team, as Monopars Chief Medical Officer, said Dr. Costa. My industry knowledge and expertise in moving cancer therapies through all stages of clinical testing is well suited to help accelerate Monopars pipeline of innovative mid- and late-stage clinical programs and early drug development candidates.

AboutMonoparTherapeuticsInc.

MonoparTherapeutics is a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients.Monopar'spipeline consists ofValidivefor the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicinfor the treatmentof advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit:www.monopartx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.Examples of these forward-looking statements include statements concerning Dr. Costa providing strategic direction for Monopars pipeline and Dr. Costa aiding in executing or accelerating Monopar clinical development. The forward-looking statements involve risks and uncertainties including, but not limited toDr. Costas unknown future contributions to Monopar and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made.Monoparundertakesno obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monoparsviews only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

CONTACT:

Monopar Therapeutics Inc:Investor RelationsKim R. TsuchimotoChief Financial Officerkimtsu@monopartx.com

Follow Monopar on social media for updates:

Twitter: @MonoparTx LinkedIn: Monopar Therapeutics